The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer

The glutamine metabolism has a key role in the regulation of uncontrolled tumour growth. This study aimed to evaluate expression and prognostic significance glutaminase luminal breast cancer (BC). isoforms (GLS/GLS2) were assessed at genomic/transcriptomic levels, using METABRIC (n = 1398) GeneMiner datasets 4712), protein immunohistochemistry well-characterised cohorts Oestrogen receptor-positive/HER2-negative BC patients: ductal carcinoma situ (DCIS; n 206) invasive (IBC; 717). Glutaminase was associated with clinicopathological features, patient outcome glutamine-metabolism-related genes. In DCIS, GLS alone GLS+/GLS2- risk factors for shorter local recurrence-free interval (p < 0.0001 p 0.001, respectively) remained independent size, grade comedo necrosis 0.0008 0.003, respectively). IBC, gene copy number gain high mRNA poor 0.011), whereas GLS2 predictive longer disease-free survival 0.006). plays biological function BC, particularly early non-invasive stage, which could be used as potential biomarker predict disease progression target inhibition. Further validation is required confirm these observations, functional assessments are needed explore their specific roles.